Skip to main content
Premium Trial:

Request an Annual Quote

Biosystemix to Analyze Data for S2K to Find Predictive Disease Markers

NEW YORK, June 21 (GenomeWeb News) - Biosystemix will develop computational models based on genomic and proteomic data for S2K, a Canadian consortium of researchers, the company said today.


Under the partnership, Biosystemix of Kingston, Canada, will use its data mining algorithms to discover predictive molecular markers and models from gene expression, proteomics, and cellular immune response data generated by S2K in the areas of HIV, HCV, rheumatoid arthritis, and transplant rejection.


Intellectual property resulting from the analyses will form the basis for commercial products such as diagnostic and prognostic markers, according to the company.


S2K's program, "Functional Genomics, Pharmacogenomics and Proteomics of the Immune Response in Health and Immune Related Disorders", is funded by Genome Canada and Genome Quebec.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.